Delivery Order SPE2DR25D3301-SPE2DR26F19KL
- Not listed
- The Defense Logistics Agency awarded a $14,996.88 firm fixed price delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections with an ultimate completion date of December 11, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling value and extends through December 2026. The...
- The Defense Logistics Agency awarded a $1,845.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL), with an ultimate completion date of November 5, 2025. This non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a firm fixed price delivery order valued at $17,749.40 for Zepbound 2.5 mg/0.5 ml pens with a completion date of July 14, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply vehicle with DLA. The product will be performed at the vendor's Conshohocken, Pennsylvania location, which serves as the company's corporate headquarters and...
- The Defense Logistics Agency awarded a $14,216.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen injections on July 30, 2025, with completion targeted for July 31, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $12,150.18 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on November 17, 2025. This non-set-aside, competitively awarded contract represents a firm fixed price delivery order with an ultimate completion date of November 18, 2025. The pharmaceutical product will be delivered to the contracting location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a $1,107.42 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 ml pen injections on December 9, 2025, with completion scheduled for December 10, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a $2,383.56 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injections. This non-competitive delivery order, with an ultimate completion date of July 15, 2025, represents a small-value pharmaceutical transaction supporting federal medical procurement needs. The award was fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $54,200.70 on December 10, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with a completion date of December 11, 2025, and represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be performed at the contractor's Conshohocken, Pennsylvania location,...
- The Defense Logistics Agency awarded a $17,498.32 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on November 24, 2025, with a completion date of November 25, 2025. This firm fixed-price contract, issued without a set-aside designation, represents a competitively awarded delivery order for a diabetes medication to support federal medical procurement needs. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $12,661.98 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 mL pen injections on August 25, 2025, with completion scheduled for August 26, 2025. This firm fixed-price delivery order, which was competitively awarded without set-aside restrictions, represents a continuation of the vendor's critical role in federal pharmaceutical procurement. The order will be fulfilled from AmerisourceBergen's location in...
- SPE2DR25D3301Indefinite Delivery Contract
- SPE2DR25D3301-SPE2DR26F19KLDelivery Order
The Defense Logistics Agency awarded a $39,945.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injections on December 11, 2025, with completion scheduled for December 12, 2025. This non-competitive, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary operations. This delivery order is part of AmerisourceBergen's comprehensive pharmaceutical supply portfolio supporting military and federal healthcare systems. As a major pharmaceutical distributor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities, AmerisourceBergen fulfills critical medical commodity needs across multiple therapeutic domains through the DLA's Pharmaceutical Prime Vendor Global Program. The Zepbound delivery represents the company's ongoing role as a primary vendor for specialty medications supporting federal medical supply chains worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $39.9k | 12/10/25 |